Oppenheimer raised the firm’s price target on ArriVent Biopharma to $39 from $35 and keeps an Outperform rating on the shares. The firm notes that on Monday, ArriVent announced promising interim data from firmonertinib’s FURTHER trial presented during the Presidential Symposium at WCLC, with additional detail shared during an afternoon investor call. This was the first reported prospective trial of any TKI in PACC mutant advanced NSCL.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma price target raised to $36 from $30 at H.C. Wainwright
- ArriVent announces PoC global Phase 1b interim data for firmonertinib
- Corbus Pharmaceuticals appoints Kung to board of directors
- ArriVent Biopharma price target raised to $30 from $25 at H.C. Wainwright
- ArriVent Biopharma reports Q2 EPS (65c), consensus (64c)